EGFR and non-small cell lung carcinoma: After removal of the dacomitinib-containing medium, no downstream phosphorylation was detected.[13] In the latest treatment guidelines, dacomitinib is used in patients with NSCLC with EGFR exon 19 deletion and L858R point mutation.